Development of a protein biomarker test for preoperative diagnosis of ovarian cancer.
Reference number | |
Coordinator | Uppsala universitet - Institutionen för immunologi, genetik och patologi |
Funding from Vinnova | SEK 2 312 500 |
Project duration | October 2017 - October 2019 |
Status | Completed |
Important results from the project
The goal of the project is to improve ovarian cancer diagnostics by developing a biomarker test that can be used to determine if women with a pelvic aberrant ultrasound need to undergo surgical diagnostics.
Expected long term effects
The project has resulted in a test based on the protein profile in a blood test that can be used to assess whether a deviating ultrasound is of a benign nature and does not require surgical diagnostics or requires surgery. The results are very promising, and the test will be offered by selected service laboratories.
Approach and implementation
The project is based on a collaboration between two universities and healthcare regions as well as a biotechnology company (Olink), with a unique technology for protein analysis. In a number of subprojects we have identified a protein profile that can be used, developed this into a test with absolute quantification, applied for a patent for this, and conducted a clinical study to show its value. The project is based on the utilization of expertise and resources from the three participating organizations.